

## SUPPLEMENT TO:

*Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma*

*Medical Oncology 2024*

Enrico Sammarco<sup>1,\*</sup>, Martina Rossetti<sup>2</sup>, Alessia Salfi<sup>3</sup>, Adele Bonato<sup>3</sup>, Paolo Viacava<sup>4</sup>, Gianluca Masi<sup>3,5</sup>, Luca Galli<sup>3</sup> and Pinuccia Faviana<sup>2</sup>

1. Medical Oncology Unit, Livorno Hospital, Azienda Toscana Nord Ovest, Livorno, Italy

2. Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy

3. Medical Oncology Unit 2, Santa Chiara Hospital, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

4. Pathology Unit, Livorno Hospital, Azienda Toscana Nord Ovest, Livorno, Italy

5. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

\*corresponding author ([enricosammarco1992@gmail.com](mailto:enricosammarco1992@gmail.com))

This appendix has been provided by the authors to give readers additional information about the work.

## List of Contents

|                                                                                           |   |
|-------------------------------------------------------------------------------------------|---|
| Table S1. Comparison between baseline characteristic and response to first-line treatment | 2 |
|-------------------------------------------------------------------------------------------|---|

| <b>Characteristic</b>                         | <b>Responders<br/>(N=12)</b> | <b>Non-responders<br/>(N=16)</b> | <b>p-value</b> |
|-----------------------------------------------|------------------------------|----------------------------------|----------------|
| <b>ECOG performance status</b>                |                              |                                  |                |
| 0                                             | 8 (66.7)                     | 10 (62.5)                        | 0.692          |
| 1                                             | 4 (33.3)                     | 4 (25.0)                         |                |
| 2                                             | 0                            | 2 (12.5)                         |                |
| <b>Histology</b>                              |                              |                                  |                |
| ccRCC, n (%)                                  | 10 (83.3)                    | 14 (87.5)                        | 1              |
| nccRCC, n (%)                                 | 2 (16.7)                     | 2 (12.5)                         |                |
| <b>Sarcomatoid features</b>                   |                              |                                  |                |
| Yes                                           | 3 (25.0)                     | 3 (18.8)                         | 1              |
| No                                            | 9 (75.0)                     | 13 (81.2)                        |                |
| <b>Nephrectomy</b>                            |                              |                                  |                |
| Yes                                           | 10 (83.3)                    | 14 (87.5)                        | 1              |
| No                                            | 2 (16.7)                     | 2 (12.5)                         |                |
| <b>Metastatic stage at initial diagnosis</b>  |                              |                                  |                |
| Yes                                           | 2 (16.7)                     | 5 (31.2)                         | 0.662          |
| No                                            | 10 (83.3)                    | 11 (68.8)                        |                |
| <b>IMDC score</b>                             |                              |                                  |                |
| Favorable                                     | 3 (25.0)                     | 0                                | 0.068          |
| Intermediate                                  | 7 (58.3)                     | 15 (93.8)                        |                |
| Poor                                          | 2 (16.7)                     | 1 (6.2)                          |                |
| <b>Type of 1st line combination treatment</b> |                              |                                  |                |
| Dual ICI                                      | 4 (33.3)                     | 8 (50.0)                         | 0.459          |
| ICI+TKI                                       | 8 (66.7)                     | 8 (50.0)                         |                |
| <b>Type of tumor sample</b>                   |                              |                                  |                |
| Primary tumor                                 | 10 (83.3)                    | 14 (87.5)                        | 1              |
| Metastasis                                    | 2 (16.7)                     | 2 (12.5)                         |                |

**Table S1.** Comparison between baseline characteristic and response to first-line treatment in the entire population